Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting  by Juan, C. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01251.x
Contribution of clonal dissemination and selection of mutants during
therapy to Pseudomonas aeruginosa antimicrobial resistance in an
intensive care unit setting
C. Juan1, O. Gutie´rrez1, A. Oliver1, J. I. Ayestara´n2, N. Borrell1 and J. L. Pe´rez1
1Servicio de Microbiologı´a and 2Servicio de Medicina Intensiva, Hospital Son Dureta, Palma de
Mallorca, Spain
ABSTRACT
Rates of antibiotic resistance in Pseudomonas aeruginosa isolates from intensive care unit (ICU) patients
are expected to be dependent on the selection of resistance mutations during therapy, the availability of
exogenous resistance determinants and their dissemination potential, and the efficiency of transmission
of the resistant strains. The relative contributions of these three factors were studied in an ICU with no
apparent outbreak in 216 sequential P. aeruginosa isolates recovered from 102 patients between
September 2002 and November 2003. Analysis of pulsed-field gel electrophoresis patterns revealed the
presence of 82 different clones. Thus, the dissemination of particular resistant clones had a minimal
effect on the relatively high overall resistance frequencies found for imipenem (32%), cefepime (25%),
ceftazidime (24%), meropenem (22%), ciprofloxacin (18%) and tobramycin (2%). Rates of primary
resistance were relatively low, and resistance development during treatment (secondary resistance) was
the main factor contributing to the overall high resistance rates. In ICU settings with a low prevalence of
epidemic resistant strains, the main strategy for resistance control should focus on the design of targeted
regimens to avoid the development of resistance.
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INTRODUCTION
Pseudomonas aeruginosa is one of the main causes
of nosocomial respiratory tract infection, and is
the primary cause of ventilator-associated pneu-
monia in the intensive care unit (ICU), where it is
associated with a high mortality rate [1]. The
extraordinary ability of P. aeruginosa to acquire
antimicrobial resistance results in severe thera-
peutic limitations, especially in ICUs, where
patients are highly susceptible to infection by
opportunistic pathogens. Underlying disease,
severity of illness, immunosuppression and the
presence of invasive devices (especially mechan-
ical ventilation) are well-known risk-factors for
P. aeruginosa infection [2,3].
There are two major mechanisms for the acqui-
sition of antimicrobial resistance by P. aeruginosa.
First, the selection of mutations resulting in
inactivation, hyper-expression or modification of
chromosomal genes may result in resistance to
multiple antimicrobial agents. Such mutations
include those leading to the hyper-expression of
the chromosomal cephalosporinase (AmpC),
thereby conferring resistance to penicillins and
cephalosporins, those resulting in inactivation of
OprD, which confers resistance to carbapenems,
or those resulting in the upregulation of one of the
several efflux pumps, thereby potentially confer-
ring resistance to multiple antimicrobial agents
such as b-lactams, fluoroquinolones and amino-
glycosides [4]. A second mechanism involves the
acquisition of new resistance determinants
through horizontal gene transfer mediated by
plasmids or transposable elements. Import-
ant examples include the acquisition of new
b-lactamases (penicillinases, cephalosporinases
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or carbapenemases) and aminoglycoside-modify-
ing enzymes, which are frequently harboured by
the same transferable elements [4]. In addition,
the frequency of antimicrobial resistance in
P. aeruginosa in a particular ICU setting depends
on the ability of different resistant P. aeruginosa
strains to colonise the ICU environment and to
disseminate between different patients. The com-
bination of these three factors, i.e., selection of
resistance mutations (highly dependent on the
efficiency of antibiotic therapy), acquisition of
new resistance determinants (highly dependent
on the availability of the transferable elements
and their dissemination potential), and the trans-
mission efficiency of the resistant strains, results
in a complex epidemiological picture for anti-
biotic-resistant strains of P. aeruginosa.
Most studies concerning the molecular epi-
demiology of antibiotic-resistant P. aeruginosa in
the ICU setting have been conducted in out-
break situations, in which a particular multi-
resistant clone has disseminated among multiple
patients, but such situations probably do not
represent the situation in most ICUs. Therefore,
the present study investigated the molecular
epidemiology of antibiotic-resistant P. aeruginosa
in an ICU with no apparent outbreak in order to
determine the relative contributions to the over-
all prevalence of resistance of primary resistance
(infection by a resistant strain), inter-patient
dissemination of resistant strains, and the selec-
tion of resistant mutants during antibiotic ther-
apy (secondary resistance).
MATERIALS AND METHODS
All P. aeruginosa isolates recovered from sequential clinical
samples from patients admitted to the ICU of Hospital Son
Dureta (Palma de Mallorca, Spain) between September 2002
and November 2003, obtained with a separation of ‡ 3 days,
were included in the study. In total, 216 isolates from 102
patients were analysed (7.5% of the patients admitted to the
ICU during this period). P. aeruginosawas isolated from at least
two sequential samples from 41 patients (average period
7.6 ± 5.8 days). Identification and initial susceptibility testing
was performed with the WIDER system (Francisco Soria
Melguizo, Madrid, Spain) [5]. The antibiotics tested were
amoxycillin, amoxycillin–clavulanate, ticarcillin, piperacillin–
tazobactam, cephalothin, cefuroxime, cefoxitin, cefotaxime,
ceftazidime, ceftazidime–clavulanate, cefepime, imipenem,
meropenem, gentamicin, tobramycin, amikacin, nalidixic acid,
ciprofloxacin, trimethoprim–sulphamethoxazole, fosfomycin
and colistin. Additionally, MICs of ceftazidime, cefepime,
imipenem, meropenem, ciprofloxacin and tobramycin were
determined by Etest (AB Biodisk, Solna, Sweden). NCCLS
breakpoints [6] were used to define resistance. MICs of
imipenem in the presence and absence of EDTA were
determined by Etest for imipenem-resistant strains to investi-
gate the possible presence of class B (metallo) acquired
carbapenemases. If the resistance pattern obtained with the
WIDER system was consistent with the production of an
extended-spectrum b-lactamase (ceftazidime resistance and
susceptibility to either piperacillin–tazobactam or ceftazidime–
clavulanate), a double-disk synergy test using amoxycillin and
ceftazidime, cefepime and aztreonam disks was performed.
Data for primary resistance were the susceptibilities of the
first P. aeruginosa isolate from each of the patients. Data for
secondary resistance were the susceptibilities of a strain
resistant to any of the tested antibiotics from a patient with a
previously susceptible strain. Information regarding the anti-
biotics received by the 102 patients before and after the
isolation of P. aeruginosawas recovered from the ICU database.
The epidemiological relatedness of the strains was studied
by pulsed-field gel electrophoresis (PFGE). Bacterial DNA
embedded in agarose plugs was digested with SpeI. DNA
separation was performed in a CHEF-DRIII apparatus (Bio-
Rad, La Jolla, CA, USA) with 6 V ⁄ cm2 for 26 h and pulse times
of 5–40 s. DNA macrorestriction patterns were interpreted
according to the criteria established by Tenover et al. [7].
Fischer’s exact test was used to compare categorical
variables, and the Student T-test and Mann–Whitney U-test
were used to compare quantitative parametric and non-
parametric variables, respectively. A p value < 0.05 was
considered to be statistically significant.
RESULTS AND DISCUSSION
The isolation sites of P. aeruginosa for the 102
patients are shown in Table 1. As expected, the
lower respiratory tract was the site of infection in
86 (84.3%) of the patients. P. aeruginosa was
isolated from one site in 79 patients, and from at
least two different sites in 23 patients. All of these
23 patients had P. aeruginosa isolated from the
lower respiratory tract (Table 1).
Table 1. Isolation site of Pseudomonas aeruginosa from 102
patients
Site
No. (%) of
patients
(n = 102)
Isolation of the
same clone from
different sites
Respiratory tract 86 (84.3)
Wound 17 (16.6)
Catheter 17 (16.6)
Urine 3 (2.9)
Blood 4 (3.9)
Others 3 (2.9)
More than one origin; respiratory tract plus:a 23 (22.5) 18
Wound 11 (10.7) 6
Catheter 11 (10.7) 11
Blood 4 (3.9) 4
Urine 3 (2.9) 3
Others 2 (1.9) 2
aSeven patients had P. aeruginosa isolated from more than two sites. In all cases,
P. aeruginosa was isolated from the respiratory tract and a catheter infection plus a
third site (urine, blood or wound).
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PFGE analysis identified 82 different clones
of P. aeruginosa among the 102 patients, with
most (n = 65; 79.2%) being isolated from single
patients. The remaining 17 (20.8%) clones were
isolated from at least two patients, with 11 clones
shared by two patients, four by three patients, one
by four patients, and one by five patients. When
the ICU admission data of patients infected with
clones that were present in three or more patients
were analysed, an overlapping temporal frame
was documented in all but one of the patients,
suggesting patient-to-patient transmission of the
strains rather than the presence of long-term
environmental reservoirs of particular clones in
the ICU.
Among the 23 patients with isolates from two
or more sites, all the patients with isolates from
the respiratory tract and catheter, blood or urine
yielded P. aeruginosa isolates belonging to the
same clone from both sites, while different clones
were found in five of 11 patients with P. aerugi-
nosa isolates from the respiratory tract and
a wound infection. In one patient, two different
P. aeruginosa strains were isolated from the same
wound site with a separation of 35 days.
Antibiotic resistance data are shown in Table 2.
Resistance percentages ranged from 1.8% for
tobramycin to 31.9% for imipenem. As would
be expected from the low level of inter-patient
transmission of strains indicated by PFGE analy-
sis, the dissemination of resistant clones had a
minimal effect on the relatively high overall
resistance percentages. Only a modest effect was
observed for imipenem, caused by the dissemin-
ation of three resistant clones among nine
patients. Consistent with these findings, and in
contrast with the overall resistance percentages,
the rates of primary resistance (Table 2) were low
or moderate for all antibiotics, with the exception
of imipenem (23.4% of the patients had primary
resistant strains), perhaps caused, in part, by the
dissemination of resistant strains.
The number and percentage of patients from
whom P. aeruginosa with secondary resistance
was isolated are displayed in Table 2. Resistance
development during antibiotic treatment was a
relatively frequent event. Thus, in 21 (20.6%)
patients, secondary resistance was observed for at
least one of the antimicrobial agents tested. When
only patients with sequential isolates (41 of 102
patients) were considered as the denominator,
secondary resistance for at least one of the
antibiotics tested reached 51%. In 20 (95%) of
these 21 patients, secondary resistance was a
consequence of mutant selection (the susceptible
and resistant isolates had the same PFGE pattern),
as opposed to replacement of the susceptible
clone by a resistant clone. Secondary resistance
development was highest for the cephalosporins,
cefepime and ceftazidime (17.5% and 15.5%,
respectively), and lowest for tobramycin (1%).
No evidence of the presence of acquired resist-
ance determinants was found in any of the
isolates. Thus, imipenem resistance was not
inhibited by EDTA in any of the strains, suggest-
ing that resistance was mediated by the classical
mutational mechanisms resulting in the reduction
of OprD expression and not by the expression of
acquired class B carbapenemases. Also, resistance
phenotypes in ceftazidime- or cefepime-resistant
isolates were consistent with AmpC hyper-
production and not with the expression of
acquired enzymes such as ESBLs. Finally, the
only four isolates resistant to tobramycin (all
belonging to the same clone and isolated from the
same patient) were secondary resistance isolates
and expressed low levels of resistance (MICs of
8–16 mg ⁄L), which is consistent with mutational
resistance, such as mexXY hyper-expression,
rather than the production of acquired aminogly-
coside-modifying enzymes.
On average, the 102 patients in the study spent
25.3 ± 20.0 days in the ICU, the interval from first
to last isolation of P. aeruginosa was 17.1 ±
18.3 days, and anti-pseudomonal therapy was
received for 19.0 ± 20.0 days. Resistance develop-
ment was associated with a longer period in the
ICU (46.3 ± 28.4 vs. 19.7 ± 12.2 days; p < 0.001), a
longer period of isolation of P. aeruginosa
(24.2 ± 22.3 vs. 9.7 ± 8.3 days; p 0.001), and a
longer period of anti-pseudomonal therapy
Table 2. Overall frequencies of primary and secondary
resistance of the Pseudomonas aeruginosa isolates
Antibiotic
No. (%) of
resistant isolates
(n = 216)a
No. (%) of patients
with primary
resistance (n = 102)a,b
No. (%) of patients
with secondary
resistance (n = 102)a,b
Ceftazidime 52 (24.0) 8 (7.8) 16 (15.7)
Cefepime 54 (25.0) 7 (6.9) 18 (17.6)
Imipenem 69 (31.9) 25 (24.5) 9 (8.8)
Meropenem 47 (21.8) 12 (11.8) 9 (8.8)
Ciprofloxacin 39 (18.0) 9 (8.8) 9 (8.8)
Tobramycin 4 (1.8) 0 (0.0) 1 (1.0)
aNumber and percentage of resistant isolates were defined according to NCCLS
non-susceptibility breakpoints, and therefore include both the intermediate and
resistant categories.
bTotal number of patients included in the study.
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(43.0 ± 26.0 vs. 15.0 ± 12.5 days; p < 0.001). Inter-
estingly, resistance development occurred after
treatment for 23.0 ± 15.2 days (i.e., 8 days more
than the average total length of treatment of
patients who did not develop resistance), suggest-
ing that prolonged anti-pseudomonal treatment is
an important risk-factor for resistance develop-
ment, which, in turn, results in a further prolon-
gation of anti-pseudomonal treatment.
The data regarding antibiotic treatment before
the development of secondary resistance are
shown in Table 3. All P. aeruginosa strains that
developed resistance to imipenem, ciprofloxacin
or tobramycin were isolated from patients treated
previously with imipenem, ciprofloxacin or
tobramycin, respectively. Interestingly, all
patients with acquired resistance to meropenem
had been treated either with meropenem or
imipenem plus a second antibiotic, namely a
fluoroquinolone or an anti-pseudomonal penicil-
lin or cephalosporin. It is also notable that most of
the patients who developed secondary resistance
to cephalosporins had been treated with carbap-
enems. Furthermore, four of the patients with
acquired resistance to cefepime had received only
a carbapenem.
The percentage of patients treated with a
particular class of antibiotic for which P. aerugi-
nosa secondary resistance development was docu-
mented are also shown in Table 3. Denominators
used were: for imipenem and meropenem, the
number of patients treated with imipenem or
meropenem; for ciprofloxacin, patients treated
with ciprofloxacin or levofloxacin; for tobramycin,
patients treated with gentamicin, tobramycin or
amikacin; and for ceftazidime and cefepime,
either patients treated with ceftazidime, cefepime
or piperacillin–tazobactam, or patients treated
with any anti-pseudomonal b-lactam, including
carbapenems (since cephalosporin resistance
development was also documented in patients
treated only with a carbapenem). With the excep-
tion of tobramycin, which was associated with a
significantly lower rate of resistance development
(1.4% of patients treated with aminoglycosides;
p < 0.001), there were no significant differences
between the antibiotics studied (Table 3).
Patients hospitalised in ICUs have a 5–10-fold
greater risk of contracting nosocomial infections
[8,9]. P. aeruginosa is one of the most frequent and
severe causes of nosocomial infections, especially
affecting ICU patients with mechanical ventilator-
Table 3. Percentage of treated patients who developed secondary resistance in relation to antibiotic treatment received
before the development of resistance
Secondary resistance (no. of patients) Treatment received before the development of resistancea Treated patients who developed resistance (%)b
Meropenem (n = 9) Meropenem (n = 2) 20.5
Imipenem (n = 7)
Imipenem + ciprofloxacin (n = 3)
Imipenem + cefepime (n = 1)
Imipenem + piperacillin–tazobactam (n = 3)
Imipenem (n = 9) Imipenem (n = 9) 20.5
Tobramycin (n = 1) Tobramycin (n = 1) 1.4
Ciprofloxacin (n = 9) Ciprofloxacin (n = 9) 26.5
Cefepime (n = 18) Cefepime (n = 3) 24 (21.4)c
Cefepime + carbapenem (n = 3)
Ceftazidime (n = 4)
Ceftazidime alone (n = 1)
Ceftazidime + imipenem (n = 2)
Ceftazidime + piperacillin–tazobactam (n = 1)
Piperacillin–tazobactam (n = 8)
Piperacillin–tazobactam alone (n = 1)
Piperacillin–tazobactam + ceftazidime (n = 1)
Piperacillin–tazobactam + carbapenem (n = 6)
Carbapenem alone (n = 4)
Ceftazidime (n = 16) Ceftazidime (n = 6) 21.3 (19.0)c
Ceftazidime alone (n = 1)
Ceftazidime + cefepime (n = 1)
Ceftazidime + piperacillin–tazobactam (n = 1)
Ceftazidime + imipenem (n = 3)
Piperacillin–tazobactam (n = 9)
Piperacillin–tazobactam alone (n = 2)
Piperacillin–tazobactam + carbapenem (n = 7)
Imipenem alone (n = 1)
aMultiple antibiotic treatment does not imply simultaneous administration.
bThe denominators used were: for imipenem and meropenem, the number of patients treated with a carbapenem; for ciprofloxacin, patients treated with a fluoroquinolone; for
tobramycin, patients treated with an aminoglycoside; and for ceftazidime and cefepime, patients treated with an anti-pseudomonal penicillin or cephalosporin (ceftazidime,
cefepime or piperacillin–tazobactam).
cPercentages obtained using the number of patients treated with any anti-pseudomonal b-lactam (including carbapenems) as the denominator, since resistance development
was also documented for ceftazidime and cefepime in some patients who received only carbapenems.
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associated pneumonia or burn wound infections,
both of which are associated with a high mortality
rate [1,10]. Antimicrobial resistance in P. aerugi-
nosa is one of the most important factors limiting
the control of these infections, frequently leading
to treatment failure with major clinical conse-
quences [11]. Outbreaks of P. aeruginosa nosoco-
mial infection, associated with epidemic clones
and mainly affecting ICU patients, have been
described previously [12–15]. These epidemic
clones tend to be associated with multiple anti-
microbial resistance, and the presence of acquired
resistance determinants, such as genes encoding
b-lactamases or aminoglycoside-modifying en-
zymes, carried by plasmids, integrons or trans-
posons, is frequent in these strains [12–14]. The
association of these efficient nosocomial clones
with multiresistance is probably a consequence of
what has been termed ‘genetic capitalism’; i.e., the
most successful clones are also more likely to
acquire resistance determinants by chance and,
because of the antibiotic pressure in the hospital
environment, are favoured for further spread [16].
In the absence of epidemic clones in a
particular setting, an endogenous source of
P. aeruginosa infections seems to be more likely
than nosocomial spread, as evidenced by the
fact that most patients in the present study were
infected by unique clones. Thus, in contrast to
previous reports [17,18], it appeared that cross-
colonisation was a relatively minor problem in
this particular setting. Consistent with this low
rate of inter-patient transmission of strains,
primary resistance was relatively low and there
was no evidence of transferable resistance
determinants. Nevertheless, the overall resis-
tance rates were relatively high for all antibiot-
ics, with the exception of tobramycin, because of
the important contribution of secondary resist-
ance. Indeed, in the absence of epidemic clones,
resistance development during therapy ap-
peared to be the main factor contributing to
the prevalence of resistance in this ICU. High
rates of mutational antibiotic resistance in
P. aeruginosa have been correlated with the
presence of hyper-mutable strains in cystic
fibrosis patients [19], but the prevalence of
hyper-mutable strains has been found previ-
ously to be low in the ICU setting [20].
When epidemic multiresistant clones are dis-
seminated widely in a particular ICU environ-
ment, primary resistance is expected to be high, so
that appropriate empirical treatments, based on
knowledge of the particular resistance patterns,
are important determinants of the success of
treatment. Implementation of infection control
measures is also crucial in such circumstances
[21,22]. In addition to these measures, the design
of targeted optimal therapeutic regimens to avoid
the development of resistance during therapy is
crucial for resistance control in settings with a low
prevalence of epidemic clones. Possible develop-
ment of cross-resistance is also an important
consideration; in this context, carbapenems may
select for cephalosporin resistance, but the oppos-
ite does not seem to be a frequent event (Table 3).
Optimisation of the pharmacokinetic–pharmaco-
dynamic indices [23,24], the use of combination
antimicrobial therapy [24], and knowledge of the
potential for development of cross-resistance, are
probably the most important factors to be consid-
ered in controlling the development of resistance
during therapy, which will also minimise the
overall resistance rates in ICUs with a low
prevalence of epidemic clones.
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